Pfizer pays $68 billion to settle illegal US marketing case of ‘Rapamune’ by Wyeth

31 Jul 2013 Evaluate

Pfizer Inc will pay a fine of $490.9 million to settle accusations of illegal marketing of the drug Rapamune by Wyeth Pharmaceuticals Inc, a company acquired by US drug giant in 2009 for a sum of $68 billion. A case was file against Wyeth for allegedly training its national Rapamune sales force to promote the use of the drug in situations not approved by the U.S. Food and Drug Administration (FDA).

Rapamune is an immunosuppressive drug that prevents the body’s immune system from rejecting a transplanted organ. It was approved in 1999 for use in kidney transplants to help keep the body's immune system from rejecting the new organ, but Wyeth was alleged to have encouraged its sales force to target all kinds of transplants.

Pfizer Inc is the parent company of Pfizer, which manufactures prescription drugs such as Viagra, Lyrica, Viagra, Dolonex Gel, Ponstan, Citralka Liquid, and many more.

Pfizer Share Price

4230.25 24.50 (0.58%)
30-Apr-2024 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1531.15
Dr. Reddys Lab 6293.65
Cipla 1413.55
Zydus Lifesciences 963.85
Lupin 1650.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.